DENTSPLY SIRONA (NASDAQ:XRAY) Cut to Hold at BidaskClub

DENTSPLY SIRONA (NASDAQ:XRAY) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Friday, March 22nd, BidAskClub reports.

A number of other equities analysts have also commented on the company. Bank of America began coverage on DENTSPLY SIRONA in a research note on Monday, March 18th. They set a “buy” rating and a $57.00 price objective on the stock. William Blair upgraded DENTSPLY SIRONA from a “market perform” rating to an “outperform” rating and set a $56.71 price objective on the stock in a research note on Monday, March 18th. UBS Group raised their price objective on DENTSPLY SIRONA from $42.00 to $53.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 12th. Zacks Investment Research upgraded DENTSPLY SIRONA from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a research note on Saturday, March 9th. Finally, Robert W. Baird raised their price objective on DENTSPLY SIRONA from $42.00 to $50.00 and gave the stock a “neutral” rating in a research note on Monday, March 4th. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the stock. DENTSPLY SIRONA currently has an average rating of “Hold” and a consensus price target of $52.12.

Shares of NASDAQ XRAY traded down $0.01 during trading hours on Friday, reaching $51.23. 763,885 shares of the stock were exchanged, compared to its average volume of 1,858,526. The firm has a market cap of $11.24 billion, a P/E ratio of 25.49, a price-to-earnings-growth ratio of 2.27 and a beta of 1.11. The company has a current ratio of 1.86, a quick ratio of 1.27 and a debt-to-equity ratio of 0.30. DENTSPLY SIRONA has a 52 week low of $33.93 and a 52 week high of $51.46.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its earnings results on Friday, March 1st. The medical instruments supplier reported $0.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.54 by $0.04. The company had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.02 billion. DENTSPLY SIRONA had a positive return on equity of 8.21% and a negative net margin of 25.36%. The firm’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter last year, the company earned $0.82 earnings per share. Analysts forecast that DENTSPLY SIRONA will post 2.31 EPS for the current year.

Hedge funds have recently modified their holdings of the business. BlackRock Inc. boosted its holdings in shares of DENTSPLY SIRONA by 1.8% during the 4th quarter. BlackRock Inc. now owns 14,334,332 shares of the medical instruments supplier’s stock valued at $533,380,000 after acquiring an additional 257,243 shares in the last quarter. Mackenzie Financial Corp boosted its holdings in shares of DENTSPLY SIRONA by 17.3% during the 4th quarter. Mackenzie Financial Corp now owns 10,090,056 shares of the medical instruments supplier’s stock valued at $375,451,000 after acquiring an additional 1,490,134 shares in the last quarter. First Eagle Investment Management LLC boosted its holdings in shares of DENTSPLY SIRONA by 315.6% during the 3rd quarter. First Eagle Investment Management LLC now owns 6,155,959 shares of the medical instruments supplier’s stock valued at $232,326,000 after acquiring an additional 4,674,605 shares in the last quarter. Morgan Stanley boosted its holdings in shares of DENTSPLY SIRONA by 1,233.9% during the 3rd quarter. Morgan Stanley now owns 5,242,702 shares of the medical instruments supplier’s stock valued at $197,860,000 after acquiring an additional 4,849,652 shares in the last quarter. Finally, Atlanta Capital Management Co. L L C boosted its holdings in shares of DENTSPLY SIRONA by 0.4% during the 3rd quarter. Atlanta Capital Management Co. L L C now owns 4,754,247 shares of the medical instruments supplier’s stock valued at $179,425,000 after acquiring an additional 18,007 shares in the last quarter. 96.30% of the stock is currently owned by hedge funds and other institutional investors.

About DENTSPLY SIRONA

DENTSPLY SIRONA Inc designs, develops, manufactures, and markets various dental and oral health products, and other consumable healthcare products primarily for the professional dental market worldwide. The company operates in two segments, Technologies & Equipment; and Consumables. Its dental supplies include endodontic instruments and materials, dental anesthetics, prophylaxis pastes, dental sealants, impression materials, restorative materials, tooth whiteners, and topical fluoride products; and small equipment products comprise dental hand pieces, intraoral curing light systems, dental diagnostic systems, and ultrasonic scalers and polishers.

Featured Story: How is a buy-side analyst different from a sell-side analyst?

Analyst Recommendations for DENTSPLY SIRONA (NASDAQ:XRAY)

Receive News & Ratings for DENTSPLY SIRONA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DENTSPLY SIRONA and related companies with MarketBeat.com's FREE daily email newsletter.